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Abstract
Introduction Pregnancy protects against breast cancer
development in humans and rats. Parous rats have persistently
reduced circulating levels of growth hormone, which may affect
the activity of the growth hormone/insulin-like growth factor
(IGF)-I axis. We investigated the effects of IGF-I on parity-
associated protection against mammary cancer.
Methods Three groups of rats were evaluated in the present
study: IGF-I-treated parous rats; parous rats that did not receive
IGF-I treatment; and age-matched virgin animals, which also did
not receive IGF-I treatment. Approximately 60 days after N-
methyl-N-nitrosourea injection, IGF-I treatment was
discontinued and all of the animal groups were implanted with a
silastic capsule containing 17β-estradiol and progesterone. The
17β-estradiol plus progesterone treatment continued for 135
days, after which the animals were killed.
Results IGF-I treatment of parous rats increased mammary
tumor incidence to 83%, as compared with 16% in parous rats
treated with 17β-estradiol plus progesterone only. Tumor
incidence and average number of tumors per animal did not
differ between IGF-I-treated parous rats and age-matched virgin
rats. At the time of N-methyl-N-nitrosourea exposure, DNA
content was lowest but the α-lactalbumin concentration highest
in the mammary glands of untreated parous rats in comparison
with age-matched virgin and IGF-I-treated parous rats. The
protein levels of estrogen receptor-α in the mammary gland was
significantly higher in the age-matched virgin animals than in
untreated parous and IGF-I-treated parous rats. Phosphorylation
(activation) of the extracellular signal-regulated kinase-1/2
(ERK1/2) and expression of the progesterone receptor were
both increased in IGF-I-treated parous rats, as compared with
those in untreated parous and age-matched virgin rats.
Expressions of cyclin D1 and transforming growth factor-β3 in the
mammary gland were lower in the age-matched virgin rats than
in the untreated parous and IGF-I-treated parous rats.
Conclusion We argue that tumor initiation (transformation and
fixation of mutations) may be similar in parous and age-matched
virgin animals, suggesting that the main differences in tumor
formation lie in differences in tumor progression caused by the
altered hormonal environment associated with parity.
Furthermore, we provide evidence supporting the notion that
tumor growth promotion seen in IGF-I-treated parous rats is
caused by activation of estrogen receptor-α via the Raf/Ras/
mitogen-activated protein kinase cascade.
Keywords: estrogen receptor-α , growth hormone/insulin-like growth factor-I, mammary carcinogenesis, mitogen-activated protein kinase progester-
one receptor
Introduction
A first full-term pregnancy early in life confers effective nat-
ural protection against breast cancer in women [1]. Rats
exhibit a similar phenomenon, in that parity prevents
ER = estrogen receptor; ERK1/2 = extracellular signal-regulated kinase-1/2; GH = growth hormone; IGF = insulin-like growth factor; MAPK = 
mitogen-activated protein kinase; MNU = N-methyl-N-nitrosourea; PI3-K = phosphatidylinositol 3-kinase; PR = progesterone receptor; TEB = terminal 
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chemically induced mammary carcinogenesis [2]. The
causes of this pregnancy-associated protection against
mammary carcinogenesis are still being investigated.
Changes in the mammary epithelia, such as high degree of
differentiation, low level of proliferation, increase in cell
cycle length, reduction in carcinogen binding to epithelial
cells, and increased capacity for DNA repair have been
associated with parity in rats [3-7]. More recently it was
shown that gene expression is altered in the mammary
gland of parous mice and rats as compared with virgin ani-
mals [8]; similarly, rats that have been made refractory to
mammary tumorigenesis by estrogen and progesterone
treatments also exhibit differences in the mammary gland
gene expression as compared with untreated rats [9]. How-
ever, the functional significance of these alterations in gene
expression in relation to the susceptibility of the mammary
gland to carcinogenesis has not been demonstrated.
Parity also causes changes in the circulating levels of hor-
mones that regulate mammary gland development and may
affect the susceptibility of the mammary gland to tumori-
genesis. For example, parity in women causes a persistent
reduction in the concentration of prolactin in serum
[10,11], and similarly parous rats have a significantly
reduced circulating concentration of growth hormone (GH)
as compared with nulliparous, age-matched animals [2].
Furthermore, in our previous studies [12] we demonstrated
that treatment of parous rats with low doses of 17β-estra-
diol and progesterone abolishes the protective effects
induced by pregnancy. Therefore, the pregnancy-associ-
ated protection against mammary cancer can be nullified by
changing the hormonal environment of the animal.
These findings cast doubts upon whether the changes in
the mammary epithelia of parous animals are permanent
phenotypical alterations or a reflection of altered hormonal
environment. As mentioned above, we found a reduction in
the circulating concentration of GH associated with parity
in rats. An increasing body of evidence now indicates that
the GH/insulin-like growth factor (IGF)-I axis is a determin-
ing factor in the susceptibility of the breast to cancer devel-
opment. Early studies showed that administration of GH
together with estrogen and progesterone restores chemi-
cally induced mammary tumorigenesis in hypophysect-
omized rats [13]. Later studies showed that inhibition of
GH secretion reduces chemically induced mammary car-
cinogenesis in rats [14,15]. Similarly, mice carrying a trans-
gene expressing GH antagonist (modified bovine GH) are
at reduced risk for developing mammary cancer as com-
pared with littermates not carrying the transgene [16]; in
contrast, mice overexpressing GH exhibit an increase in
mammary cancer development as compared with mice with
normal GH levels [17].
Direct effects of IGF-I on normal mammary gland develop-
ment and mammary carcinogenesis are also evident. IGF-I-
deficient (knockout) mice exhibit very limited mammary epi-
thelial development [18]; this defect was remedied by IGF-
I and 17β-estradiol treatment, whereas 17β-estradiol treat-
ment alone was ineffective. Overexpression of IGF-I trans-
gene targeted to the mammary gland by placing it under the
control of whey acidic protein promoter inhibits involution
of the mammary epithelia after lactation, indicating that IGF-
I acts as a survival factor for the mammary epithelia [19,20].
This inhibition of involution is acquired, at least partly,
through reduction in apoptosis of mammary cells [19,21].
Furthermore, continuous breeding of mice carrying the
whey acidic protein promoter-regulated IGF-I transgene
results in mammary cancer development, albeit after a long
latency period [21].
Epidemiologic studies have shown that a high circulating
concentration of IGF-I is correlated with increased risk for
breast cancer development [22], and GH and IGF-I con-
centrations in serum are elevated in breast cancer patients
[23,24]. How the GH/IGF-I axis affects mammary tumori-
genesis is not well established. The mitogenic activity of
IGF-I in normal mammary epithelia is well known [25], and
GH has been shown to regulate estrogen receptor (ER)
expression in the mammary gland [26]. Indeed, we have
found a significant reduction in levels of ER in mammary
gland of parous rats as compared with age-matched virgin
animals [2]. In the present study we investigated the effects




Female Sprague–Dawley rats, 6–15 per group, were kept
in a 14-hour light/10-hour dark lighting schedule, and were
given free access to food and water. To generate parous
animals, virgin rats were mated at 50–55 days of age. After
parturition, the pups were removed and the mammary
glands of the mothers were allowed to involute for 40 days.
At that time, the parous rats were used for experimentation.
N-methyl-N-nitrosourea (MNU) was purchased from Ashe
Stevens (Detroit, MI, USA) and administered in a single
intraperitoneal injection [27]. Three groups of rats were
used in the experiments. In one group, parous rats were
treated with recombinant human IGF-I (Genentech Inc.,
South San Francisco, CA, USA) at a dose of 0.660 mg/kg
body weight per day, administered via an Alzet osmotic
pump (Durect, Cupertino, CA, USA), for 60 days com-
mencing 7 days before MNU injection and continued for an
additional 53 days. The second group included parous rats
that did not receive any IGF-I treatment. The third group
included age-matched virgin control animals, which also
did not receive any IGF-I treatment. Approximately 60 days
after the MNU injection, 1 week after the IGF-I treatmentAvailable online http://breast-cancer-research.com/content/6/4/R423
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was terminated, all animals were implanted with a silastic
capsule [28] containing 20 µg 17β-estradiol (Sigma, St
Louis, MO, USA) and 20 mg progesterone (Sigma). The
capsules were changed every 2 months. The 17β-estradiol
plus progesterone treatment was continued for 135 days,
after which all animals were killed. To assess the develop-
ment of the mammary gland and the serum concentrations
of IGF-I at the time of carcinogen administration, animals
from each of the three groups were killed 7 days after com-
mencement of treatment. Normal mammary tissues and
serum were collected and stored at -80°C until they were
analyzed (Fig. 1).
Wholemounts were prepared from the right second and
third glands from the animals and used for assessment of
mammary development. The frozen mammary tissues were
used for Western blot analyses as described below and to
assess total DNA, α-lactalbumin, and IGF-I contents of the
mammary gland.
The MNU-treated animals were palpated weekly for detec-
tion of mammary tumors and tumors were removed from the
animals under anesthesia when they had grown to 1.5 cm
in diameter. At the time of tumor collection, a small sample
was excised from each tumor for histologic classification.
The serum samples were used to measure the circulating
concentrations of IGF-I at the time of MNU injection.
The care and use of animals in the study was approved by
the Chancellor's Animal Care Committee at the University
of California at Santa Cruz.
Assessment of α-lactalbumin in mammary tissues
The content of α-lactalbumin in the mammary tissues was
used as an indicator of differentiation of the mammary epi-
thelia at the time of carcinogen exposure. The tissues were
ground to a fine powder in liquid nitrogen with pestle and
mortar and then homogenized on ice with a Polytron
homogenizer (Brinkmann Instruments Inc., Burlingame, CA,
USA) in 2 volumes (weight/vol) of 50 mmol/l Tris-HCl, 5
mmol/l MgCl2 buffer (pH 7.5) containing 1 mmol/l Pefabloc
(Roche Molecular Biochemicals, Indianapolis, IN, USA)
and 1 µmol/l Pepstatin A (Sigma). After the tissues had
been homogenized, 20 µl samples were obtained and used
for measuring the total DNA content of the preparation, and
the remainder of the samples were extracted for 1 hour and
then centrifuged at 20,000 g for 30 min; both steps were
conducted at 4°C. The supernatant was collected and
used to measure total protein and α-lactalbumin concentra-
tion. A radioimmunoassay, specific for rat α-lactalbumin,
was developed. Rat α-lactalbumin was purified from rat
milk in accordance with a previously established method
[29]. Antiserum generated against rat α-lactalbumin was
generously provided by Dr Kurt E Ebner at the University of
Kansas Medical Center. The within and between coeffi-
cient variations of the assay were 3.0% and 18.4%,
respectively.
Wholemount preparation and tumor histology
Mammary gland wholemounts were prepared as described
previously [30]. Briefly, animals were killed and pinned
down on a corkboard, ventral side up. A skin incision was
made between the nipples and down both the hind legs,
Figure 1
Schematic representation of the animal treatments used in the present study Schematic representation of the animal treatments used in the present study. E2, 17β-estradiol; IGF, insulin-like growth factor; MNU, N-methyl-N-
nitrosourea; P4, progesterone.Breast Cancer Research    Vol 6 No 4    Thordarson et al.
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creating a cut in the shape of an inverted 'Y'. The mammary
glands were exposed, and the right second and third
glands removed and fixed in 10% buffered formalin. After
de-fatting the tissue in acetone, the mammary epithelia was
stained with iron/hematoxylin and inspected under a micro-
scope for assessment of overall development. All tumors
were classified microscopically. For that, a small specimen
was obtained, fixed in 4% paraformaldehyde, embedded in
paraffin, and sectioned. The sections were then stained
with hematoxylin and eosin and classified.
Measurement of IGF-I concentration in mammary 
tissues
IGF-I was extracted from the mammary glands as has pre-
viously been described [31]. Briefly, the tissues were pul-
verized as described above, homogenized in 1 N acetic
acid (1 g tissue/5 ml acetic acid), and extracted on ice for
2 hours. After centrifugation at 20,000 g for 6 min, the
supernatant was collected and the tissues extracted again
as before, and the two extractions for each sample were
combined and lyophilized. The lyophilized material was
reconstituted in 50 mmol/l Tris/HCl (pH 7.8) at 1 g original
wet weight of tissue per 2 ml buffer and assayed using radi-
oimmunoassays for rat and, for those animals treated with
human IGF-I, for human IGF-I (Diagnostic Systems Labora-
tories, Webster, TX, USA) either undiluted or diluted in
assay buffer.
Protein and DNA assays
The serum concentrations of endogenous IGF-I and exog-
enous IGF-I (human IGF-I in treated rats) were assessed
using radioimmunoassay kits from Diagnostic Systems
Laboratories, as described above. The protein concentra-
tions of extracted mammary samples were measured with
BCA protein assay kit (Pierce, Rockford, IL, USA) using
bovine serum albumin (Sigma) as the reference standard.
The total DNA content of the mammary gland homogenates
was assessed by fluorometric DNA assay [29] using calf
thymus DNA (Sigma) as reference standard.
Western blot analyses
Western blot analyses were carried out as recently
described [32]. Briefly, mammary gland tissues were
homogenized and extracted, and solubilized protein elec-
trophorized on 7.5–20% SDS-PAGE, depending on the
size of the protein being analyzed, at 50–100 µg total pro-
tein/lane, as determined by BCA protein assay (Pierce).
Proteins were transferred to a PVDF membrane and the
specific protein bands detected using chemiluminescence
reagents and CL-X Posure™ Film (Pierce). Western blot
analyses were carried out on cyclin D1 using antibody sc-
450 (Santa Cruz Biotechnology, Santa Cruz, CA, USA);
total ER-α using antibody Ab-15 (NeoMarkers Inc., Fre-
mont, CA, USA); progesterone receptor (PR) using anti-
body no. A 0098 (DakoCytomation Inc., Carpinteria, CA,
USA); total and phosphorylated extracellular signal-regu-
lated kinase-1/2 (ERK1/2) using antibodies #9102 and
#9106, respectively (Cell Signaling Technology Inc., Bev-
erly, MA, USA); and transforming growth factor (TGF)-β3
using antibody GF16 (Oncogene Research Product, San
Diego, CA, USA). Protein bands, detected with chemilumi-
nescence, were quantified using the ImageJ (version
1.24o) image analysis program (National Institutes of
Health, Bethesda, MD, USA).
Statistics
Incidence of mammary cancer was analyzed using 2 × 2
contingency tables and χ2 tests. All other statistical analy-
ses were carried out using analysis of variance and Fisher's
protected least significant difference test. P < 0.05 was
considered statistically significant.
Results
T r e a t m e n t  o f  p a r o u s  r a t s  w i t h  0 . 6 6  m g  I G F - I / k g  b o d y
weight per day resulted in an increase in the circulating
concentration of total IGF-I to 2289.2 ± 68.8 ng/ml (mean
± standard error), which was a significantly higher concen-
tration than that found in intact parous and age-matched
virgin rats (Fig. 2a). The IGF-I concentration in the mam-
mary tissues at the time of carcinogen exposure was also
elevated in the IGF-I-treated parous animals as compared
with untreated parous rats, but did not differ significantly
between IGF-I-treated parous and age-matched virgin ani-
mals (Fig. 2b). Body weight gain did not differ between the
animal groups, when assessed at the time of MNU injection
and at the termination of the experiment (Table 1). How-
ever, the elevation of IGF-I in parous rats caused a signifi-
cant increase in mammary tumor incidence as compared
with parous rats treated only with 17β-estradiol plus pro-
gesterone, beginning 60 days after the MNU injection.
Tumor incidence in IGF-I-treated parous rats and age-
matched virgin rats that also received 17β-estradiol and
progesterone treatment 60 days after MNU injection did
not differ significantly, and neither did the average number
of tumors per animal in these two groups (Table 2). All the
animals that did carry mammary tumors developed at least
one carcinoma (mostly ductal, papillary, and cribriform car-
cinomas). Development of fibroadenoma was rare (only 6–
7%) and did not differ between IGF-I-treated parous and
age-matched virgin rats.
The total DNA content of the mammary glands was signifi-
cantly lower in the parous rats that did not receive IGF-I
treatment, as compared with IGF-I-treated parous rats and
age-matched virgin animals (Fig. 3). The stage of differenti-
ation, as measured using the content of α-lactalbumin in
the mammary gland, was significantly higher in mammary
tissues from untreated parous rats compared with IGF-I-
treated parous and age-matched virgin rats (Fig. 4). Inspec-
tion of the whole mounts revealed that the epithelialAvailable online http://breast-cancer-research.com/content/6/4/R423
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structures were less dense in the parous untreated rats
than in the parous IGF-I-treated and particularly in the age-
matched virgin rats. Also apparent from the inspection of
the whole mounts was that terminal end-buds (TEBs) were
present in all of the animal groups and did not appear to be
less abundant in the parous untreated animals than in age-
matched virgin and IGF-I-treated parous rats (Fig. 5). These
structures are traditionally associated with a high rate of
epithelial proliferation and high susceptibility to cancer
development.
The total protein level of ER-α in the mammary gland at the
time of carcinogen injection was significantly higher in age-
matched virgin animals than in untreated parous rats, and
treatment of parous rats with IGF-I further lowered the con-
centration of ER-α (Fig. 6). Phosphorylation of ERK1/2 was
significantly increased in mammary tissues of IGF-I-treated
parous rats, whereas the lowest level of phosphorylation of
ERK1/2 was found in the mammary tissues from untreated
parous rats (Fig. 7). No difference was found in the levels
of total ERK1/2 expression in mammary glands from the
three groups of rats (Fig. 8). Like phosphorylation of ERK1/
2, the expression of PR in mammary tissues was signifi-
cantly elevated in animals treated with IGF-I, but PR expres-
sion was lowest in untreated parous animals (Fig. 9).
Expression of cyclin D1 was lowest in mammary gland from
age-matched virgin animals but was similar in mammary tis-
sues from the two parous groups (Fig. 10). Similarly, the
levels of TGF-β3 were found to be lowest in mammary
glands from age-matched virgin rats, but TGF-β3 did not dif-
fer in mammary tissues obtained from the untreated and
IGF-I-treated parous animals (Fig. 11).
Discussion
Several years ago we found that the circulating levels of
GH and, to a lesser extent, of prolactin are significantly
reduced in parous rats, and we speculated that this
reduction in serum concentration of GH might be a deter-
mining factor in the reduced susceptibility of the mammary
gland to cancer development associated with parity [2].
Much other evidence links GH and/or IGF-I (the GH/IGF-I
axis) with both normal mammary gland development
[25,33] and possible involvement in carcinogenesis of the
breast [34,35]. In the present study we demonstrated that
IGF-I treatment increases mammary tumorigenesis in
parous rats to a level similar to that in age-matched virgin
animals. We also previously showed that long-term treat-
ments of parous rats with low doses of 17β-estradiol and
progesterone obliterate the parity-associated protection
against mammary cancer [12]. In addition, it has been
shown that dissociated mammary epithelial cells obtained
from MNU-treated young virgin rats develop fewer tumors
and exhibit a longer latency period when transplanted into
parous syngeneic hosts as compared with cells trans-
planted into virgin syngeneic hosts [36].
The prevailing hypothesis regarding how parity protects the
breast against cancer development has been that the mam-
mary epithelia consist of undifferentiated, fast-growing TEB
and terminal duct structures that are highly susceptible to
carcinogenesis, and of differentiated, slow-growing
alveolar structures that exhibit refractoriness to cancer
development. Extensive differentiation of the mammary
gland seen at parturition rids the gland of the fast-growing
susceptible TEBs and terminal ducts, replacing them with
Figure 2
Insulin-like growth factor (IGF)-I concentration in (a) serum and (b)  mammary tissues of parous rats treated with insulin-like growth factor  (IGF)-I (P-IGF-I), untreated parous rats (P-Un), and age-matched virgin  rats (AMV) Insulin-like growth factor (IGF)-I concentration in (a) serum and (b) 
mammary tissues of parous rats treated with insulin-like growth factor 
(IGF)-I (P-IGF-I), untreated parous rats (P-Un), and age-matched virgin 
rats (AMV). IGF-I treatment (0.66 mg/kg body weight/day) was contin-
ued for 7 days before samples were collected. IGF-I concentrations for 
P-IGF-I rats are combined endogenous (rat IGF-I) and exogenous 
(human IGF-I) values. Values are expressed as mean ± standard error. 
*P < 0.05: versus AMV and P-Un in panel a, and versus P-Un in panel 
b.Breast Cancer Research    Vol 6 No 4    Thordarson et al.
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the differentiated, refractory alveolar structures. Accompa-
nying the reduction in the proliferation rate of the mammary
epithelia of the parous animals are other changes, such as
increased capacity for DNA repair, decreased binding of
the carcinogen to the DNA, and increased length of cell
cycle.
According to this hypothesis, this condition of the mam-
mary gland is retained after involution of the gland; that is,
differentiation of the mammary gland acquired during
pregnancy is a permanent state [3-7]. It is now clear, based
on a number of studies, that this hypothesis inadequately
explains the differences in susceptibility of mammary gland
to tumorigenesis between virgin and parous animals. First,
it has long been questioned whether there is much differ-
ence in the proliferative activity of the mammary gland of vir-
gin as compared with parous rats. In terms of structure,
TEBs are as abundant in the mammary gland of parous as
they are in virgin rats [12,37], which we confirmed in the
present study. Assessment of proliferation confirms find-
ings from the structural studies. Using thymidine incorpora-
tion, Sinha and coworkers [37] did not find any difference
in labeling index between mammary glands from parous
and age-matched virgin animals at the time of carcinogen
exposure.
However, this study and previous reports support the
notion that the mammary gland maintains higher levels of
differentiation, at least in terms of milk-specific protein
expression, after pregnancy or hormonal treatment that
causes pregnancy-like development of the gland, as
compared with mammary glands of virgin, intact animals
[8,9,12]. Nevertheless, it has been difficult to demonstrate
an association between a previous differentiated state of
the mammary gland and its subsequent susceptibility to
tumorigenesis. For example, stimulating the development of
the mammary gland almost to a lactational state by
increasing the circulating levels of prolactin and progester-
one without changing the 17β-estradiol concentration in
serum does not confer protection of the gland against
MNU-induced carcinogenesis, whereas treatment of the
animals with 17β-estradiol either alone or with progester-
one does provide protection [38]. Also, Rajkumar and cow-
orkers [39] were unable to establish a good correlation
between mammary differentiation and 17β-estradiol-
induced protection against tumorigenesis, in that full pro-
tection was conferred after a short-term estrogen treatment
without full lobule–alveolar development. Similarly, Medina
and coworkers [40] found a discrepancy between
mammary development and the level of protection using
low doses of estrogen and progesterone, and termination
of pregnancy before any significant differentiation of the
mammary gland has taken place confers partial protection
against mammary tumorigenesis [37]. Further refuting the
notion that differentiation of the mammary gland is a prereq-
uisite for refractoriness to tumorigenesis, and supporting
the claim that the hormonal environment is the determining
factor, is the finding that virgin Sprague–Dawley dwarf rats
lacking functional GH, caused by a point mutation of the gh
gene [41], exhibit the same refractoriness to mammary tum-




Groups Body weight (g) at MNU injection (mean ± SEM) Body Wt. (g) at Sacrifice (mean ± SEM)
P-Un 286 ± 3.2 (n = 7) 303 ± 3.5 (n = 6)
P-IGF-I 286 ± 6.2 (n = 7) 317 ± 4.5 (n = 6)
AMV 293 ± 5.4 (n = 7) 309 ± 9.6 (n = 6)
Body weight at the time of N-methyl-N-nitrosourea (MNU) injection and just before the animals were killed at the termination of the experiment for 
untreated parous rats (P-Un), parous rats treated with insulin-like growth factor-I (P-IGF-I), and untreated virgin rats that were age matched with 
the parous animals (AMV).
Table 2
Mammary carcinogenesis in N-methyl-N-nitrosourea injected rats
Groups Cancer incidence (%) Cancer load number/rat (mean ± SEM) Latency range (days)
P-UN (n = 6) 16* 0.167 121
P-IGF-I (n = 6) 83 2.17 ± 0.75 57–176
AMV (n = 6) 100 2.20 ± 0.45 92–217
Mammary tumor incidence, latency, and load in untreated parous rats (P-Un), parous rats treated with insulin-like growth factor -I, and in virgin rats 
that were age matched with the parous animals (AMV). *P < 0.05 versus P-IGF-I and AMV.Available online http://breast-cancer-research.com/content/6/4/R423
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As mentioned above, we reported earlier [2] that the circu-
lating concentrations of both GH and prolactin are reduced
in parous rats as compared with age-matched virgin rats.
Importantly, it has now been demonstrated that short-term
treatment of virgin rats with 17β-estradiol alone or in
combination with progesterone, to achieve circulating lev-
els of these hormones comparable to those seen in late
pregnant animals, confers mammary tumor refractoriness
and significant reduction in the circulating concentrations
of GH and prolactin [44]. Furthermore, GH-deficient
Sprague–Dawley dwarf rats exhibit the same refractoriness
to mammary tumorigenesis that is seen in parous rats
[42,43], but when treated with GH the dwarf rats acquire
the same high susceptibility seen in normal virgin Sprague–
Dawley rats [43]. Also, in the present study we show that
the same increase in mammary tumorigenesis can be
achieved by treating the parous rats with IGF-I. Therefore,
it is unequivocal that the activity of the GH/IGF-I axis is fun-
damental in determining the level of mammary carcinogen-
esis. However, the question remains as to how the
hormonal environment affects the mammary gland to
increase or decrease its tumorigenesis. Will the answer be
found in a difference in expression of specific genes in the
mammary gland at the time of carcinogen exposure, caus-
ing an increase/decrease in transformation upon carcino-
gen exposure?
Using DNA microarrays, D'Cruz and coworkers [8] identi-
fied a number of genes that were differentially expressed in
mammary glands from parous and virgin rats and mice.
Similarly, Ginger and coworkers [9] used a subtractive sup-
pressive hybridization method to analyze the differences in
gene expression of the mammary gland from susceptible
(intact virgin) and refractory (estrogen and progesterone
treated) Wistar–Furth rats. Again, a number of genes were
found to be differentially expressed in the susceptible and
refractory glands, but it remains to be seen whether any of
these differentially expressed genes are involved in
determining the susceptibility of the mammary gland to
tumor development.
We studied here the expression of a few specific genes
that we considered likely to be important for the suscepti-
bility of the mammary gland to carcinogenesis. However,
we found it difficult to relate an increase or a decrease in
gene expression to an increase or a decrease in tumorigen-
esis of the mammary gland at the time of carcinogen expo-
sure. For example, we found the lowest expression of the
ER-α in mammary tissues from IGF-I-treated parous rats,
but mammary tumorigenesis in these animals was the same
as in age-matched virgin rats. The same difficulties are
encountered when interpreting the results for expression
levels of cyclin D1 and TGF-β3. Cyclin D1, which is a cell
cycle regulator [45] and causes mammary cancer when
overexpressed, as evident from studies in the cyclin D1
transgenic mouse model [46], did not correlate well with
tumorigenesis, with the lowest expression occurring in ani-
mals with the highest tumorigenesis (age-matched virgin
rats). D'Cruz and coworkers [8] previously showed that
cyclin D1 mRNA levels are increased in the mammary gland
of parous rats as compared with age-matched virgin ani-
Figure 3
The total DNA content of mammary glands of parous rats treated with  insulin-like growth factor (IGF)-I (P-IGF-I), untreated parous rats (P-Un),  and age-matched virgin rats (AMV) The total DNA content of mammary glands of parous rats treated with 
insulin-like growth factor (IGF)-I (P-IGF-I), untreated parous rats (P-Un), 
and age-matched virgin rats (AMV). The IGF-I treatment (0.66 mg/kg 
body weight/day) was continued for 7 days before samples were col-
lected. Values are expressed as mean ± standard error. *P < 0.05 ver-
sus AMV and P-IGF-I.
Figure 4
The concentration of α-lactalbumin (α-lac) in mammary tissues  obtained from parous rats treated with insulin-like growth factor (IGF)-I  (P-IGF-I), untreated parous rats (P-Un), and age-matched virgin rats  (AMV) The concentration of α-lactalbumin (α-lac) in mammary tissues 
obtained from parous rats treated with insulin-like growth factor (IGF)-I 
(P-IGF-I), untreated parous rats (P-Un), and age-matched virgin rats 
(AMV). The IGF-I treatment (0.66 mg/kg body weight/day) was contin-
ued for 7 days before samples were collected. Values are expressed as 
mean ± standard error. *P < 0.05 versus AMV and P-IGF-I.Breast Cancer Research    Vol 6 No 4    Thordarson et al.
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mals. Also, as D'Cruz and coworkers reported, we found
the lowest level of TGF-β3 expression in mammary tissues
of age-matched virgin rats, which is a possible indication of
a high proliferation rate [47], but no difference was found in
mammary tissues obtained from untreated and IGF-I-
treated parous animals, although tumorigenesis in these
two parous groups differs significantly.
It should also be considered in this context that there might
actually not be much, if any, difference in susceptibility to
tumor initiation (transformation and fixation of mutation)
between mammary glands of parous and virgin animals. It
was recently demonstrated that tumor formation does
occur in the mammary gland of parous rats, with incidence
rate and multiplicity similar to that in age-matched virgin
Figure 5
Photomicrographs showing mammary gland wholemounts from parous rats treated with insulin-like growth factor (IGF)-I (upper row, panel a; lower  row, panel a), untreated parous rats (upper row, panel b; lower row, panel b), and age-matched virgin rats (upper row, panel c; lower row, panel c) Photomicrographs showing mammary gland wholemounts from parous rats treated with insulin-like growth factor (IGF)-I (upper row, panel a; lower 
row, panel a), untreated parous rats (upper row, panel b; lower row, panel b), and age-matched virgin rats (upper row, panel c; lower row, panel c). 
The IGF-I treatment (0.66 mg/kg body weight/day) was continued for 7 days before the animals were killed and the wholemounts were prepared. 
Note the smaller alveolar structures of the mammary epithelia from parous animals, particularly untreated parous rats, as compared with the age-
matched virgin rats (upper row of panels) and the presence of terminal end-buds in the mammary glands from all groups (lower row of panels). Mag-
nifications: 6.25× (upper row) and 10× (lower row).Available online http://breast-cancer-research.com/content/6/4/R423
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rats [48]. However, these tumors stay largely latent at
microscopic size and grow only to a palpable size upon
hormonal stimulation, as we demonstrated here and
showed in previous studies [12]. That is, tumor formation
does occur in the mammary epithelia of parous rats, but the
hormonal environment of these animals is altered to the
extent that it is not capable of promoting tumor progres-
sion. Supporting the notion that the difference in palpable
mammary tumor development between parous and virgin
animals lies primarily in the promotion of growth, but not in
transformation, is the fact that the protection – conferred
either by pregnancy or by hormonal treatment – is equally
effective regardless of whether it takes place before or after
exposure to the carcinogen [38,39,48]. Importantly, preg-
nancy-associated protection, when applied after carcino-
gen exposure, does not rid the gland of the transformed
cells during the differentiation and involution processes as
evident by the fact that microtumors are present in the
mammary gland of parous animals regardless of whether
the carcinogen exposure takes place before or after preg-
nancy occurs [48].
Therefore, tumor formation does take place in the mammary
gland of parous rats with frequency almost equal to that in
age-matched virgin animals, but only the tumors in the
virgin rats progress to palpable size. We do not yet
understand the reason for this, but the differences here
must be subtle and may only become apparent after the
transformation of the mammary tissue. That is, parity would
have little effects on growth of normal mammary tissues,
but after transformation the environment of the mammary
tumors will not stimulate growth of the cancerous cells. It is
not an unknown phenomenon that mammary tumors
require different environmental factors for growth from
those of normal mammary epithelia. For example, some 40
years ago Huggins and coworkers [49] demonstrated that
treatment of rats carrying chemically induced mammary
cancers with 17β-estradiol and progesterone destroyed
over 50% of their tumors, whereas the same hormonal
treatment caused an ample development of the normal
mammary epithelia. They also pointed out that hormonal
deprivation, such as ovariectomy, kills a large percentage of
hormone dependent mammary tumors, whereas the normal
mammary epithelia remain viable, only exhibiting slower
growth and metabolic rates [49]. Also, when normal mam-
mary epithelia from virgin rats are transplanted into the
cleared fat pad of parous rats, growth of these normal cells
Figure 6
Western blot analysis showing estrogen receptor (ER)-α expression in  mammary gland extracts from parous rats treated with insulin-like  growth factor (IGF)-I (P-IGF-I), untreated parous rats (P-Un), and age- matched virgin rats (AMV) Western blot analysis showing estrogen receptor (ER)-α expression in 
mammary gland extracts from parous rats treated with insulin-like 
growth factor (IGF)-I (P-IGF-I), untreated parous rats (P-Un), and age-
matched virgin rats (AMV). The IGF-I treatment (0.66 mg/kg body 
weight/day) was continued for 7 days before samples were collected. 
The protein samples (100 µg/lane) were electrophorized on 7.5% 
SDS-PAGE, transferred to PVDF membrane, and probed with antibody 
specific to ER-α(Ab-15; NeoMarkers Inc., Fremont, CA, USA). Protein 
bands were detected using enhanced chemiluminescence reagents 
(upper image) and quantified using the ImageJ (version 1.24o; National 
Institutes of Health, Bethesda, MD, USA) image analysis program (bar 
chart). Values are expressed as mean ± standard error. *P < 0.05 ver-
sus P-IGF-I and P-Un.
Figure 7
Western blot analysis showing the level of phosphorylation of extracel- lular signal-regulated kinase-1/2 (pERK1/2) in mammary tissues from  parous rats treated with insulin-like growth factor (IGF)-I (P-IGF-I),  untreated parous rats (P-Un), and age-matched virgin rats (AMV) Western blot analysis showing the level of phosphorylation of extracel-
lular signal-regulated kinase-1/2 (pERK1/2) in mammary tissues from 
parous rats treated with insulin-like growth factor (IGF)-I (P-IGF-I), 
untreated parous rats (P-Un), and age-matched virgin rats (AMV). The 
IGF-I treatment (0.66 mg/kg body weight/day) was continued for 7 
days before samples were collected. The protein samples (50 µg/lane) 
were electrophorized on 10% SDS-PAGE, transferred to PVDF mem-
brane, and probed with antibody generated to phosphorylated form of 
human ERK1/2 (#9106; Cell Signaling Technology Inc., Beverly, MA, 
USA). Protein bands were detected using enhanced chemilumines-
cence reagents (upper image) and quantified using the ImageJ (version 
1.24o; National Institutes of Health, Bethesda, MD, USA) image analy-
sis program (bar chart). Values are expressed as mean ± standard 
error. *P < 0.05 versus P-Un and AMV.Breast Cancer Research    Vol 6 No 4    Thordarson et al.
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is no different from the growth of normal cells transplanted
into virgin host. That is, the hormonal environment of the
parous animals is just as capable of stimulating growth of
normal mammary epithelia as the environment of the virgin
hosts. However, when transformed epithelial cells are
transplanted into cleared fat pads of virgin and parous
hosts, the hormonal environment of the virgin hosts is
significantly more favorable for growth of the transformed
cells than that of the parous animals [36].
When we administered IGF-I to the parous animals, the
environment of the transformed cells was sufficiently
altered for them to progress to palpable tumors. The
growth promoting activity of IGF-I on mammary cancer cells
is well established. For example, when a number of different
mitogens were tested for growth promoting activity in MCF-
7 and T47D breast cancer cells, IGF-I was shown to have
the highest mitogenic activity [50]. We found in the present
study that although the total expression of ERK1/2 did not
differ between the animal groups, the activity
(phosphorylation) of ERK1/2 was significantly elevated in
IGF-I-treated rats as compared with the other groups. This
indicates that activity of the Raf/Ras/mitogen-activated pro-
tein kinase (MAPK) cascade was significantly increased in
the mammary glands of IGF-I-treated animals. Concomitant
with the increased activity of the Raf/Ras/MAPK cascade,
we found a significant increase in the expression of the PR
in mammary tissues from IGF-I-treated parous rats.
Because ERK1/2 phosphorylates (activates) ER-α [51]
and because ER-α is an essential regulator of the expres-
sion of PR [52], we conclude from these results that the
IGF-I treatment caused increased activation of the MAPK
cascade, resulting in increased activation of ER-α, which in
turn enhanced its transcriptional activity and tumor growth.
Interactions between the IGF-I and ER-α/17β-estradiol in
regulating mammary gland development are unequivocal.
For example, very limited mammary epithelial development
will take place in the total absence of IGF-I, as
demonstrated using the IGF-I-/-  mouse model, and
administration of 17β-estradiol alone, even in supraphysio-
logical doses, was completely ineffective in restoring mam-
mary epithelial growth in the IGF-I knockout animals [18].
Thus, ER-α is practically inactive in the mammary gland in
the absence of IGF-I. IGF-I stimulates the expression of
Figure 8
Western blot analysis showing the level of total extracellular signal-reg- ulated kinase-1/2 (ERK1/2) in mammary tissues from parous rats  treated with insulin-like growth factor (IGF)-I (P-IGF-I), untreated parous  rats (P-Un), and age-matched virgin rats (AMV) Western blot analysis showing the level of total extracellular signal-reg-
ulated kinase-1/2 (ERK1/2) in mammary tissues from parous rats 
treated with insulin-like growth factor (IGF)-I (P-IGF-I), untreated parous 
rats (P-Un), and age-matched virgin rats (AMV). The IGF-I treatment 
(0.66 mg/kg body weight/day) was continued for 7 days before sam-
ples were collected. The protein samples (50 µg/lane) were electro-
phorized on 10% SDS-PAGE, transferred to PVDF membrane, and 
probed with antibody generated to rat ERK1/2 (#9102; Cell Signaling 
Technology Inc., Beverly, MA, USA). Protein bands were detected 
using enhanced chemiluminescence reagents (upper image) and quan-
tified with the ImageJ (version 1.24o; National Institutes of Health, 
Bethesda, MD, USA) image analysis program (bar chart). Values are 
expressed as mean ± standard error.
Figure 9
Levels of progesterone receptor (PR) in mammary glands obtained from  parous rats treated with insulin-like growth factor (IGF)-I (P-IGF-I),  untreated parous rats (P-Un), and age-matched virgin rats (AMV) Levels of progesterone receptor (PR) in mammary glands obtained from 
parous rats treated with insulin-like growth factor (IGF)-I (P-IGF-I), 
untreated parous rats (P-Un), and age-matched virgin rats (AMV). The 
IGF-I treatment (0.66 mg/kg body weight/day) was continued for 7 
days before samples were collected. Protein samples (50 µg/lane) 
were electrophorized on a 7.5% SDS-PAGE; Western blot analysis 
was carried out using a specific anti-PR antibody (no. A 0098; DakoCy-
tomation Inc., Carpinteria, CA, USA) and specific protein bands 
detected using enhanced chemiluminescence reagents. The upper 
image shows the results of the Western blot analysis and the bar chart 
shows the quantitation and statistical analysis of the results. Values are 
expressed as mean ± standard error. *P < 0.05 versus P-Un and AMV.Available online http://breast-cancer-research.com/content/6/4/R423
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17β-estradiol-regulated genes such as the PR, pS2, and
LIV-1 in breast cancer cells, apparently through the ER-α,
because this IGF-I activity is obliterated by antiestrogens
[53,54]. Furthermore, the Raf/Ras/MAPK cascade is one
of the major cell signaling systems to mediate the effect of
IGF-I on ER-α [51]. Therefore, we demonstrated in the
present study that IGF-I acts very similarly in the mammary
gland when administered in vivo as it does when used for
cultured breast cancer cells, in that ER-α is activated via
the Raf/Ras/MAPK cascade.
Further delineating the similarity between this rat study and
studies carried out on cultured breast cancer cells is the
recent finding that IGF-I treatment of MCF-7 cells sharply
reduces the total expression of the ER-α, while significantly
increasing the expression of the PR and pS2 – an activity
that is blocked with antiestrogen [55,56]. Those investiga-
tors showed that the phosphatidylinositol 3-kinase (PI3-K)/
Act pathway was involved in regulating the enhanced PR
expression. However, the effects of the PI3-K/Act pathway
on PR expression is complex, because Cue and coworkers
[57] found an indication of an IGF-I-induced inhibition of PR
expression mediated through the PI3-K/Act cascade – an
activity completely independent of ER-α. Therefore, the
effects of IGF-I on PR expression may differ depending on
whether they are achieved through stimulating ER-α activity
or they are mediated independent of ER-α.
How the two major signal transduction system activated by
IGF-I receptor/IGF-I, the PI3-K/Act pathway and the Raf/
Ras/MAPK cascade interact to coordinate the activity of
IGF-I in the mammary epithelia is still largely an unanswered
question, but the two signaling pathways appear to have
extensive interactions with each other [58,59]. Also, we do
not know whether IGF-I is acting here independent of 17β-
estradiol to stimulate ER-α, but results from cell culture
studies have shown that IGF-I can activate ER-α in the
complete absence of estrogen [53,54,60] as well as acting
with 17β-estradiol [53,56] to stimulate ER-α. However, we
predict that 17β-estradiol is indispensable from the IGF-I
activity described here.
The IGF-I stimulated increase in ER-α activity could be of
fundamental importance to mammary tumor progression in
the parous animals. We know that regulation of ER-α in nor-
Figure 10
The expression of cyclin D1 in the mammary gland of parous rats treated  with insulin-like growth factor (IGF)-I (P-IGF-I), untreated parous rats (P- Un), and age-matched virgin rats (AMV) The expression of cyclin D1 in the mammary gland of parous rats treated 
with insulin-like growth factor (IGF)-I (P-IGF-I), untreated parous rats (P-
Un), and age-matched virgin rats (AMV). The IGF-I treatment (0.66 mg/
kg body weight/day) was continued for 7 days before samples were 
collected. Protein samples (100 µg/lane) were electrophorized on a 
10% SDS-PAGE, transferred to a PVDF membrane, and specific pro-
tein bands detected using a specific cyclin D1 antibody (sc-450; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) and enhanced chemilumi-
nescence reagents. The upper image shows the results of the Western 
blot analysis and the bar chart shows the quantitation and statistical 
analysis of the results. Values are expressed as mean ± standard error. 
*P < 0.05 versus P-Un and P-IGF-I.
Figure 11
Levels of transforming growth factor (TGF)-β3 in mammary glands  obtained from parous rats treated with insulin-like grwoth factor (IGF)-I  (P-IGF-I), untreated parous rats (P-Un), and age-matched virgin rats  (AMV) Levels of transforming growth factor (TGF)-β3 in mammary glands 
obtained from parous rats treated with insulin-like growth factor (IGF)-I 
(P-IGF-I), untreated parous rats (P-Un), and age-matched virgin rats 
(AMV). The IGF-I treatment (0.66 mg/kg body weight/day) was contin-
ued for 7 days before samples were collected. Protein samples (100 
µg/lane) were electrophorized on a 20% SDS-PAGE; Western blot 
analysis was carried out using a specific anti-TGF-β3 antibody (GF16; 
Oncogene Research Product, San Diego, CA, USA) and specific pro-
tein bands detected using enhanced chemiluminescence reagents. The 
upper image shows the results of the Western blot analysis and the bar 
chart shows the quantitation and statistical analysis of the results. Val-
ues are expressed as mean ± standard error. *P < 0.05 versus P-Un 
and P-IGF-I.Breast Cancer Research    Vol 6 No 4    Thordarson et al.
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mal tissues is under tight control; for example, increased
ER-α activity by estrogen administration causes a sharp
downregulation in ER-α [52,61]. We have seen that admin-
istering low doses of 17β-estradiol to parous rats, while
unequivocally causing a significant stimulation of mammary
development and a large increase in mammary tumorigen-
esis, will cause a significant reduction in mRNA levels of
ER-α in the normal mammary gland as compared with
those in untreated parous rats that are refractory to tumori-
genesis and age-matched virgin animals. However, no dif-
ference was found in ER-α l e v e l s  i n  t u m o r s  f r o m  1 7 β-
estradiol-treated parous rats and age-matched virgin ani-
mals (Thordarson G, McCarty M, unpublished data). That
is, the tight regulation of ER-α appears to be diminished in
mammary tumors compared with normal mammary tissue in
that its ligand-mediated down-regulation is lost or at least
substantially blunted. This is supported by our previous
study, which showed that ER expression is significantly
increased in MNU-induced rat mammary tumors as com-
pared with normal mammary tissue [2], and may resemble
what has been described in the human breast where a
dissociation is found between ER expression and prolifera-
tion of normal mammary epithelia, but this dissociation is
lost, or is weaker, in breast cancer [62]. We hypothesize
that this lax regulation of ER-α in transformed cells is a
fundamental step in tumor development, because an
increase in ER-α activity, caused by 17β-estradiol or other
agents that are capable of activating the ER-α, no longer
provides negative feedback on ER-α expression, leading to
uncontrolled growth and ultimately tumor formation.
Conclusions
IGF-I treatment increases the level of mammary tumorigen-
esis in parous rats to that in age-matched virgin animals.
Based on expression analyses of genes that are known to
regulate mammary gland development, we found no clear
indication of differences in the susceptibility of the mam-
mary tissues from parous and age-matched virgin rats at
the time of carcinogen exposure. However, we did find
strong evidence for an increase in the growth promoting
activity of mammary tissues from IGF-I-treated rats as com-
pared with animals not receiving IGF-I treatment, in that the
activity of the MAPK cascade was elevated with a concom-
itant increase in activation of ER-α. Furthermore, we
hypothesize that the cancerous mammary epithelial cells
sustain a defect in the ligand-dependent downregulation of
ER-α, and that this defect in regulation of ER-α causes
uncontrolled growth of the transformed cells in a hormonal
environment with stimulatory pressure on the ER-α system,
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